nephros inc - NEPH

NEPH

Close Chg Chg %
4.36 0.31 7.11%

Open Market

4.67

+0.31 (7.11%)

Volume: 24.27K

Last Updated:

Sep 9, 2026, 2:17 PM EDT

Company Overview: nephros inc - NEPH

NEPH Key Data

Open

$4.36

Day Range

4.35 - 4.73

52 Week Range

2.66 - 6.42

Market Cap

$44.09M

Shares Outstanding

10.86M

Public Float

9.41M

Beta

1.56

Rev. Per Employee

N/A

P/E Ratio

25.94

EPS

$0.16

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

32.73K

 

NEPH Performance

1 Week
 
7.39%
 
1 Month
 
3.56%
 
3 Months
 
30.54%
 
1 Year
 
2.35%
 
5 Years
 
-49.42%
 

NEPH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About nephros inc - NEPH

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

NEPH At a Glance

Nephros, Inc.
380 Lackawanna Place
South Orange, New Jersey 07079
Phone 1-201-343-5202 Revenue 18.79M
Industry Medical Specialties Net Income 1.19M
Sector Health Technology 2025 Sales Growth 32.672%
Fiscal Year-end 12 / 2026 Employees 36
View SEC Filings

NEPH Valuation

P/E Current 25.942
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 44.812
Price to Sales Ratio 2.849
Price to Book Ratio 5.092
Price to Cash Flow Ratio 32.54
Enterprise Value to EBITDA 38.248
Enterprise Value to Sales 2.618
Total Debt to Enterprise Value 0.022

NEPH Efficiency

Revenue/Employee 521,916.667
Income Per Employee 33,166.667
Receivables Turnover 7.783
Total Asset Turnover 1.512

NEPH Liquidity

Current Ratio 4.056
Quick Ratio 2.888
Cash Ratio 1.952

NEPH Profitability

Gross Margin 61.126
Operating Margin 6.099
Pretax Margin 6.419
Net Margin 6.355
Return on Assets 9.609
Return on Equity 12.711
Return on Total Capital 10.599
Return on Invested Capital 11.636

NEPH Capital Structure

Total Debt to Total Equity 10.42
Total Debt to Total Capital 9.436
Total Debt to Total Assets 7.793
Long-Term Debt to Equity 6.587
Long-Term Debt to Total Capital 5.965
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nephros Inc - NEPH

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
9.97M 14.24M 14.16M 18.79M
Sales Growth
-4.12% +42.74% -0.53% +32.67%
Cost of Goods Sold (COGS) incl D&A
5.52M 6.05M 5.57M 7.30M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
571.00K 214.00K 137.00K 140.00K
Depreciation
429.00K 39.00K 46.00K 55.00K
Amortization of Intangibles
142.00K 175.00K 91.00K 85.00K
COGS Growth
+11.83% +9.51% -7.82% +31.04%
Gross Income
4.45M 8.19M 8.59M 11.48M
Gross Income Growth
-18.53% +83.94% +4.85% +33.73%
Gross Profit Margin
+44.64% +57.53% +60.64% +61.13%
2022 2023 2024 2025 5-year trend
SG&A Expense
8.79M 9.78M 8.58M 10.34M
Research & Development
1.24M 873.00K 906.00K 1.34M
Other SG&A
7.55M 8.91M 7.68M 9.00M
SGA Growth
-10.34% +11.33% -12.29% +20.47%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(4.33M) (1.59M) 6.00K 1.15M
Non Operating Income/Expense
78.00K 20.00K 84.00K 61.00K
Non-Operating Interest Income
14.00K 64.00K 94.00K 139.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
20.00K 2.00K 1.00K 1.00K
Interest Expense Growth
- -51.22% -90.00% -50.00%
Gross Interest Expense
20.00K 2.00K 1.00K 1.00K
Interest Capitalized
- - - -
-
Pretax Income
(4.28M) (1.57M) 89.00K 1.21M
Pretax Income Growth
-10.60% +63.18% +105.65% +1,255.06%
Pretax Margin
-42.88% -11.06% +0.63% +6.42%
Income Tax
- - 15.00K 12.00K
-
Income Tax - Current - Domestic
- - 15.00K 12.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (276.00K)
-
Consolidated Net Income
(4.55M) (1.57M) 74.00K 1.19M
Minority Interest Expense
- - - -
-
Net Income
(4.55M) (1.57M) 74.00K 1.19M
Net Income Growth
-10.86% +65.41% +104.70% +1,513.51%
Net Margin Growth
-45.64% -11.06% +0.52% +6.35%
Extraordinaries & Discontinued Operations
- - - (2.83M)
-
Discontinued Operations
- - - (2.83M)
-
Net Income After Extraordinaries
(7.38M) (1.57M) 74.00K 1.19M
Preferred Dividends
- - - -
-
Net Income Available to Common
(7.38M) (1.57M) 74.00K 1.19M
EPS (Basic)
-0.7169 -0.1516 0.007 0.1125
EPS (Basic) Growth
-74.85% +78.85% +104.62% +1,507.14%
Basic Shares Outstanding
10.30M 10.39M 10.53M 10.61M
EPS (Diluted)
-0.7169 -0.1516 0.007 0.1089
EPS (Diluted) Growth
-74.85% +78.85% +104.62% +1,455.71%
Diluted Shares Outstanding
10.30M 10.39M 10.60M 10.97M
EBITDA
(3.76M) (1.38M) 143.00K 1.29M
EBITDA Growth
+1.16% +63.36% +110.37% +799.30%
EBITDA Margin
-37.73% -9.69% +1.01% +6.84%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 6.00
Number of Ratings 3 Current Quarters Estimate 0.023
FY Report Date 09 / 2026 Current Year's Estimate 0.157
Last Quarter’s Earnings 0.11 Median PE on CY Estimate N/A
Year Ago Earnings 0.11 Next Fiscal Year Estimate 0.26
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 2
Mean Estimate 0.02 0.02 0.16 0.26
High Estimates 0.03 0.03 0.17 0.31
Low Estimate 0.02 0.01 0.15 0.21
Coefficient of Variance 24.75 69.28 7.37 27.20

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 1 1 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Nephros Inc - NEPH

Date Name Shares Transaction Value
Aug 17, 2026 Arthur H. Amron Director 140,874 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Nephros Inc in the News